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Abstract. Tauopathies, such as Alzheimer’s disease (AD) and Frontotemporal dementia 
with Parkinsonism linked to chromosome 17 (FTDP-17), are characterized by tau 
accumulation. This accumulation could result from alterations in tau degradation by 
either the ubiquitin-proteasome system or the autophagy–lysosomal pathway. To 
analyze a possible alteration of the autophagy–lysosomal pathway in transgenic mice 
expressing human tau with three FTDP-17 missense mutations (TauVLW mice), we 
studied the lysosomal enzyme Cathepsin D. The hippocampi of TauVLW mice, where 
the human mutant tau accumulates, showed both increased Cathepsin D and partial 
colocalization of Cathepsin D with human mutant tau. At the ultrastructural level, 
some multivesicular bodies showed human mutant tau-immunopositive vesicles. This 
finding could provide insights into the molecular mechanisms of tau degradation in 
human tauopathies. 
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INTRODUCTION 
Tau is an axonal cytosolic protein whose best known function is to promote 
microtubule assembly and sta19 bilization [1]. However, accumulation of aggregated 
insoluble tau is a hallmark of many neurodegener21 ative diseases, including 
Alzheimer’s disease (AD), progressive supranuclear palsy, and Frontotemporal 
dementia with Parkinsonism linked to chromosome 17 (FTDP-17). Collectively, these 
disorders are referred to as tauopathies [2]. Since tau inclusions are a feature of 
tauopathies, tau processing has been examined extensively in both in vitro and in vivo 
models. The investigations have focused either on post-translational modification of 
tau [3] or on mechanisms of tau degradation [4].  
Two major proteolytic systems contribute to tau degradation inside cells, the 
ubiquitin–proteasome system and the autophagy–lysosomal system [4, 5]. Indeed, as 
it does for other proteins, proteasome/ubiquitin-proteasome may degrade natively-
unfolded 35tau. Many studies have proposed increased lysosomal function as a 
strategy for reducing proteinaccumulation in age-related disorders [6]. Although tau 
clearance probably occurs through different mechanisms, there are some 
experimental evidences supporting tau degradation in lysosomes [7–9] and thus 
lysosomal dysfunction could also induce tau pathology [10].  
Under normal conditions, the lysosomal system serves as an important site for 
intracellular protein turnover and proteolytic processing of certain proteins mediated 
by lysosomal hydrolases called cathepsins. Cathepsins are lysosomal proteases whose 
enzymatic activity is conferred by critical residues, e.g., serine, cysteine, or aspartic 
acid. CathepsinDis the main lysosomal aspartic protease and is widely expressed in the 
brain, including the cortex, hippocampus, and striatum [11]. Tau can be degraded in 
vitro by Cathepsin D [12] and experiments using cell models show that lysosomes are 
involved in the degradation of tau [7, 9]. Also, Cathepsin D upregulation has been 
described in AD and its extracellular presence in senile plaques was clearly noted [13]. 
In order to study the mechanisms underlying tau pathology in vivo, the TauVLW 
transgenic mouse line was generated as a model of tauopathy. This transgenic mouse 
line expresses the longest central nervous system isoform of human tau carrying the 
three FTDP-17 missense mutations G272V, P301L, and R406W under the control of the 
thy1 promoter to direct neuron-specific expression. Although they do not appear to 
suffer altered memory functions [14],  TauVLW mice develop filamentous tau 
aggregates and lysosomal/endosomal abnormalities in hippocampal and cortical 
regions [15]. 
In the present work, we have analyzed the levels and localization of human mutant tau 
in the hip pocampus of TauVLW mice at three different ages. In addition, we have 
studied Cathepsin D localization in the same brain and at the same three ages, 
comparing wild type mice with transgenic mice. In order to determine tau localization 
in lysosomal compartments,we have performed co-localization experiments using the 
confocal microscope, ultrastructural studies,  lysosomal fraction analysis in the 
hippocampus of transgenic mice. Our data suggest that part of the human mutant tau 
in the hippocampus of transgenic mice could be degraded inside lysosomes by 
Cathepsin D. 
MATERIALS AND METHODS 
Animals 
 Detailed characterizations of TauVLW mouse lines have been previously published 
[15]. In brief, the TauVLW line overexpresses the largest human tau isoform of the 
central nervous system containing the two N-terminal inserts, four microtubule-
binding repeat elements, and three FTDP-17-linked mutations  (G207V, P301L, 
andR406W) driven by themouse thy1 promoter in the C57BL6jxCBA hybrid 
background. 
Wild type mice belong to the C57BL6j background.  This work used a total of 25 
transgenic mice and 18 wild type mice aged 1.5, 3, and 24 months old. Some mice 
were intraperitoneally anesthetized with a pentobarbital solution and perfused with 
4% paraformaldehyde in phosphate buffered saline (PBS)  pH 7.4 before postfixing 
their brains by immersion 24 h in the same fixative for immunohistochemical studies. 
Brains for electron microscopy study were fixed by perfusion with 4% 
paraformaldehyde (Panreac) and 0.2% glutaraldehyde (MERK) in PBS. After washing in 
PBS, brains were sectioned at 30 m in the sagittal plane on a vibrotome (Lancer). 
Sections were stained with thionine or immunostained with different anti- bodies. For 
the western blot studies, other mice were killed and their brains rapidly removed and 
frozen at −80ºC until use. All animals were bred at the Centro de Biolog´ıa Molecular 
“Severo Ochoa” (Madrid, Spain). Four or five mice were housed per cage, with food 
and water ad libitum, in a temperature-controlled environment with a normal dark-
light cycle (12 h of light/12 h of dark). Animals were handled according to the 
European Union guidelines (86/609/ECC) approved by the Bioethics Commission of the 
Universidad Aut´onoma de Madrid, so as to minimize their suffering and to reduce the 
number of animals to the minimum.  
Antibodies  
The following primary antibodies were used: mouse monoclonal anti-human tau HT7 
(Thermo Scientific, USA), goat polyclonal anti-Cathepsin D R-20 (Santa Cruz 
Biotechnology, California), rabbit polyclonal anti-Cathepsin D (Calbiochem, Germany), 
rabbit polyclonal anti-LAMP-2 (Igp96; Invitrogen, CA), mouse monoclonal anti--actin 
(SIGMA), rabbit polyclonal anti-TOM20(translocase of outer mitochondrial 
membranes, sc-11415; Santa Cruz Biotechnology, California) and anti-
GADPH(ABCAM;Cambridge, UK). Sources of other commercial antibodies were as 
follows. Secondary horseradish peroxidase anti-goat and biotynilated secondary 
antibody were obtained from Santa Cruz Biotechnology. Alexa-conjugated secondary 
antibodies were purchased from Invitrogen. Secondary horseradish peroxidase anti-
mouse was from DAKO (Denmark) and streptavidin-peroxidase from Biomakor. 
Colloidal gold (1 nm)-labeled Goat- anti-Mouse IgG Ultra-Small from AURION (The 
Netherlands).  
Western blot analysis  
Extracts from hippocampi of transgenic and wild type mice (1.5-, 3-, and 24-months-
old) were prepared by homogenizing in ice-cold lysis buffer (20mM HEPES, pH 7.4, 
100mM NaCl, 50mM NaF, 5mM EDTA, 1% Triton X-100, 1mM sodium orthovanadate, 
1mMpyrophosphates, 0.1mMokadaic acid, and protease inhibitor cocktail (COMPLETE, 
Roche). 
The protein concentration of samples was determined using the Bradford assay [16]. 
Total protein (10–50g) was electrophoresed on 12% or 10% SDS-PAGE for Cathepsin D 
or for tau, respectively, and electrophoretically transferred to a nitrocellulose 
membrane (PROTRAN, Whatman). The experiments were performed using the 
following primary antibodies: anti-Cathepsin D R-20 (0.7g/ml), anti-human tauHT7 
(1:5000–1:10000) and anti--actin (1:10000). 
The membranes were incubated with the antibody overnight at 4ºC in 3% BSA in PBS 
and 0.1% Tween 20. After four rinses/washes, the membrane was incubated with a 
horseradish peroxidase anti-goat (1:4000) or anti-mouse (1:5000–1:10000) IgG 
conjugate, followed by severalwashes in PBS-Tween20.The immunoreactive 
proteinswere visualized using aWestern Lightning Plus-ECL (Perkin Elmer Life, Sciences, 
MA USA). Each western blot was repeated at least three times. Blots were quantified 
using the EPSON Perfection 1660 scanner and the ImageJ1.46r image analysis system. 
The levels of various markers were normalized to the -actin present in each band. 
Immunohistochemistry 
Sagittal sections of transgenic and wild type mice of different ages were processed free 
floating using the biotin-streptavidin-peroxidase method, with diaminobenzidine (DAB) 
as a chromogen. Endoge nous peroxidasewas inactivated by incubating sections in a 
solution of 0.3% hydrogen peroxide in methanol for 30min. Sections were then 
incubated in 10% normal horse or rabbit serum in phosphate buffered saline for 1 h. 
The following antibodies were used: anti-Cathepsin D R-20 (1:200) and anti-human tau 
HT7 (1:250), overnight at 4ºC. Next day, the sections were incubated with the 
corresponding biotynilated secondary antibody (1:200) at room temperature for 1 h, 
followed by streptavidin-peroxidase (1:1200) at room temperature for 1 h. In order to 
rule out non specific staining, preabsorption of secondary antibody was performed 
with additional sections, for 24 h at 4ºC. To evaluate the specificity of the primary 
antibody staining adjacent sections were incubated in vehicle solution without the 
primary antibody. For light microscopy, some immunostained sections were  with 
thionine. The sections were examined and photographed in a NIKON light microscope. 
For electron microscopy, sections were postfixed in 2% OsO4 for 1 h, dehydrated, 
embedded in araldite, and mounted in Formvard-coated slides using plastic coverslips. 
After polymerization, selected areas of hippocampus were photographed, trimmed 
and resectioned at 1.5m. These semithin sections were rephotographed and 
resectioned in ultrathin sections (60–40 nm). The ultrathin sections were examined in 
a Jeol 301 electron microscope without heavy metal staining to avoid artifactual 
precipitates. Double immunofluorescence and confocal microscopy in brain sections  
Additional vibratome sections were processed for double-immunofluorescence 
labelling. Non-specific binding sites were blocked with 10% normal donkey serum in 
PBS at room temperature. The sections were incubated at 4◦C overnight with anti-
Cathepsin D (1:500; Calbiochem) and with anti-human tau HT7 (1:1000). After washing 
in PBS, the sections were incubated in the dark with the mixture of secondary 
antibodies: Alexa 488-conjugated anti-rabbit and Alexa 555-conjugated anti-mouse 
(1:400, Invitrogen) for 45 min at room temperature. After washing in PBS, sections 
were stained with a saturated solution of Sudan black B (SIGMA, Spain) for 30 min to 
block autofluorescence, rinsed in 70% ethanol and washed in distilled water. The 
sections were mounted in Prolong Mounting medium (Molecular Probes), sealed, and 
dried overnight. The specificity of the labeling confirmed by incubation of sections with 
the secondary antibody, omitting the primary antibody. No immunoreactivity was 
observed under these conditions.  
Colocalization analysis 
Confocal images were obtained using a TCS SP5 Spectral Leica Confocal microscope 
using an oilimmersion 63X objective with sequential-acquisition setting. The detector 
pinholes were set to give a 0.3m optical slice (lysosomal average size is 0.5–1.5 m). 
Comparisons of the degree of colocalization between tau and Cathepsin D were 
performed on stacks using orthogonal projection in merged panels with a Leica LAS AF 
software. Subcellular fractionation Hippocampus from TauVLW and wild type mice 
(three 1.5–month-old animals per group) were homogenized in cold 0.3 mol/L sucrose 
in PBS with protease vanadate, 1mMpyrophosphates, 0.1mMokadaic acid, and 
protease inhibitor cocktail (COMPLETE, Roche). 
The protein concentration of samples was determined using the Bradford assay [16]. 
Total protein  (10–50g) was electrophoresed on 12% or 10% SDS-PAGE for Cathepsin D 
or for tau, respectively, and electrophoretically transferred to a nitrocellulose 
membrane (PROTRAN, Whatman). The experiments were performed using the 
following primary antibodies: anti-Cathepsin D R-20 (0.7g/ml), anti-human tauHT7 
(1:5000–1:10000) and anti--actin (1:10000). 
 The membranes were incubated with the antibody overnight at 4ºC in 3% BSA in PBS 
and 0.1% Tween 20. After four rinses/washes, the membrane was incubated with a 
horseradish peroxidase anti-goat (1:4000) or anti-mouse (1:5000–1:10000) IgG 
conjugate, followed by severalwashes in PBS-Tween20.The immunoreactive 
proteinswere visualized using aWestern Lightning Plus-ECL (Perkin Elmer Life, Sciences, 
MA USA). Each western blot was repeated at least three times. 
Blots were quantified using the EPSON Perfection 1660 scanner and the ImageJ1.46r 
image analysis system. The levels of various markers were normalized to the -actin 
present in each band. 
Immunohistochemistry 
Sagittal sections of transgenic and wild type mice of different ages were processed free 
floating using the biotin-streptavidin-peroxidase method, with diaminobenzidine (DAB) 
as a chromogen. Endogenous peroxidasewas inactivated by incubating sections in a 
solution of 0.3% hydrogen peroxide in methanol for 30min. Sections were then 
incubated in 10% normal horse or rabbit serum in phosphate buffered saline for 1 h. 
The following antibodies were used: anti-Cathepsin D R-20 (1:200) and anti-human tau 
HT7 (1:250), overnight at 4ºC. Next day, the sections were incubated with the 
corresponding biotynilated antibody (1:200) at room temperature for 1 h, followed by 
streptavidin-peroxidase (1:1200) at room temperature for 1 h. In order to rule out non 
specific staining, preabsorption of secondary antibody was performed with additional 
sections, for 24 h at 4ºC. To evaluate the specificity of the primary antibody staining 
adjacent sections were incubated in vehicle solution without the primary antibody. For 
light microscopy, some immunostained sections were counterstained with thionine. 
The sections were examined and photographed in a NIKON light microscope. 
For electron microscopy, sections were postfixed in 2% OsO4 for 1 h, dehydrated, 
embedded in araldite, and mounted in Formvard-coated slides using plas- 200 tic 
coverslips. After polymerization, selected areas of hippocampus were photographed, 
trimmed and resectioned at 1.5m. These semithin sections were rephotographed and 
resectioned in ultrathin sections (60–40 nm). The ultrathin sections were examined in 
a Jeol 301 electron microscope without heavy metal staining to avoid artifactual 
precipitates. Double immunofluorescence and confocal microscopy in brain sections 
Additional vibratome sections were processed for double-immunofluorescence 
labelling. Non-specific binding sites were blocked with 10% normal donkey serum in 
PBS at room temperature. The sections were incubated at 4◦C overnight with anti-
Cathepsin D (1:500; Calbiochem) and with anti-human tauHT7 (1:1000). After washing 
in PBS, the sections were incubated in the dark with the mixture of secondary 
antibodies: Alexa 488-conjugated anti-rabbit and Alexa 555-conjugated anti-mouse 
(1:400, Invitrogen) for 45 min at room temperature. After washing in PBS, sections 
were stained with a saturated solution of Sudan black B (SIGMA, Spain) for 30 min to 
block autofluorescence, rinsed in 70% ethanol and washed in distilled water. The 
sections were mounted in Prolong Mounting medium (Molecular Probes), sealed, and 
dried overnight. The specificity of the labeling was confirmed by incubation of sections 
with the secondary antibody, omitting the primary antibody. No immunoreactivity was 
observed under these conditions.  
Colocalization analysis 
Confocal images were obtained using a TCS SP5 Spectral Leica Confocal microscope 
using an oilimmersion 63X objective with sequential-acquisition setting. The detector 
pinholes were set to give a 0.3m optical slice (lysosomal average size is 0.5–1.5 m). 236 
Comparisons of the degree of colocalization between tau and Cathepsin D were 
performed on stacks using orthogonal projection in merged panels with a Leica  LAS AF 
software. 240 
Subcellular fractionation Hippocampus from TauVLW and wild type mice (three 1.5–
month-old animals per group) were homogenized in cold 0.3 mol/L sucrose in PBS with 
protease inhibitors. Homogenates were centrifuged at 700 g to pellet the nuclei and 
intact cell debris. Supernatant was centrifuged at 10,000 g for 10min to sediment the 
crude lysosomal-mitochondrial fraction which was re-homogenized in 10ml of 
300mmol/L sucrose, containing 1mmol/L CaCl2. The new homogenate was incubated 
at 37ºC for 5min for mitochondria swallowing; after adding 10ml of 50% Percoll 
solution the homogenate was centrifuged at 10,000 g for 10min to obtain the 
lysosomal fraction. Fractions were equalized and immunoblotted with anti-LAMP2 
(1:2000), anti-Cathepsin D R-20 (0.7 g/ml), HT7 (1:1000), anti-TOM 20 (1:1000), and 
anti-GADPH (1:5000) antibodies. Membranes were incubated with appropriate 
horseradish peroxidase-conjugated secondary antibodies (1:2000), and visualized using 
an ECL detection kit. 
Double-labeling immunohistochemistry Immunoperoxidase detection of Cathepsin D  
followed by immunogold–silver detection of tau using a pre-embedding 
immunoperoxidase and immunogold–silver labeling method previously described by 
Sirerol-Piquer et al. [17]. As the primary antisera against Cathepsin D and tau were 
raised in goat and mice, respectively, recognition could be achieved by utilization of 
appropriate species-specific antibodies. All the incubations were carried out at room 
temperature with continuous on a rotator. The sections were placed in 0.1 M 
phosphate-buffer (PB) containing 1% sodium borohydride to inactivate residual 
aldehyde groups in the tissue sections. Sections were then washed with 0.1 M PB 
several times until the solution was clear of bubbles. Sections were then incubated in 
10% normal horse serum in 0.1 M Tris-buffered saline (TBS) for 1 h. After blocking, the 
sections were incubated in a mixture of anti-Cathepsin D R-20 (1:200) and anti-human 
tau HT7 (1:250), overnight at 4ºC. In negative control experiments, sections were 
processed for dual peroxidase and gold labeling with omission of either one or both 
antisera. 
For immunoperoxidase visualization of Cathepsin D, we used the biotin-streptavidin-
peroxidase method, with diaminobenzidine (DAB) as a chromogen. Following the 
incubation in primary antisera, the sections were incubated in secondary biotinylated 
horse antigoat IgG (1:200, Vector Laboratories, Burlingame, CA, USA) for 1 h and 
followed by streptavidinperoxidase (1:1200) at room temperature for another hour. 
After the peroxidase reaction was completed, the sections were transferred to 0.01 M 
PBS, and subsequently incubated for 10 min in 0.8% BSA and 0.1% gelatin in PBS, a 
blocking step to minimize nonspecific binding of gold particles to tissue.  
For immunogold–silver labeling, the sections were then incubated for 2 h in colloidal 
gold (1 nm)-labeled goat anti-mouse IgG (1:50) and fixed for 10 min in 2% 
glutaraldehyde in 0.01 M PBS. Incubation in 0.2 M sodium citrate buffer prior to silver 
intensification of the bound gold particleswas used to remove phosphate ions which 
could result in precipitation of silver particles. Then, sections were reacted with a silver 
solution R-GENT-SE-EM kit (AURION) for 4–8 min for electron microscopy.  
For electron microscopy, selected immunolabeled sections were fixed as described 
above. 310 
Data analysis  
Data obtained by densitometry were descriptively analyzed with Excel and are 
presented as the mean±SEM from a minimum of three separate experiments.  
Data were analyzed by the Shapiro-Wilk test to determine if the variables follow a 
normal distribution with the R2.14.0 program. Normal variables were subjected to 
Student’s t-test and non-normal variables were subjected to a non-parametric test, the 
Mann-Whitney U-test, using the SPSS17.0 program for statistical comparison. 
Statistical significance was inferred at p < 0.05.  
RESULTS  
Expression of human TauVLW transgenic protein: Immunoblotting analysis In 
previouswork, Lim et al. described the pattern and levels of expression of human 
mutant tau in the murine model TauVLW, using biochemical and immunohisto-
chemical approaches with the human-specific anti-Tau antibody T14 [15]. In the 
current study, we wanted to confirm the expression of human mutant tau protein in 
transgenic TauVLW mice with a new antibody, HT7. This antibody, which only 
recognizes human tau, reacted with a peptide corresponding to the transgene product 
(Fig. 1A). Hippocampus of TauVLW mice at 1.5, 3, and 24 months of age was dissected 
out and human tau protein levels were examined in the extracts by western blot. The 
difference in the total protein amount between the samples was normalized by -actin 
band intensity. The hippocampus of TauVLW mice showed an increase in the human 
tau levels at 3-months-old as compared to 1.5-months-old (Fig. 1B, ∗∗∗344 p = 0.0001). 
These results agreewith those obtained by Lim and coworkers using the same animal 
model 1.5- and 5.5-months-old [15]. Aging is a known risk factor for 
neurodegenerative disorders; therefore we completed the study by analyzing human 
mutant tau levels in 24-months-old mice (Fig. 1A). The data revealed significant 
differences betweenmice at 24 and1.5 months of age (∗∗351 p = 0.001), but no 
statistically significant differences were observed as compared with 3-months-old mice 
(Fig. 1B). These results suggest that human mutant tau had reached the peak of its 
expression at 3 months of age in the TauVLW mice.We could conclude that results 
obtained with HT7 antibody are consistent with previous studies performed with T14 
antibody in the samemurinemodel and, also, we extended the study to 24 months of 
age. 
Expression of human TauVLW transgenic protein: Immunohistochemistry analysis We 
next evaluated expression of human mutant tau by immunohistochemical experiments 
with HT7  antibody in vibratome sagittal brain sections from 1.5- and 24-months-old 
wild type and TauVLW mice (Fig. 1C-H).Wild typemice showed no staining,which 
revealed the high specificity of the HT7 antibody, indicating that it does not recognize 
murine tau (Fig. 1C, F). In the hippocampus of TauVLW mice, we observed a 
somatodendritic staining of human mutant tau with HT7 antibody at all ages studied. 
In the hippocampus of 1.5-months-old transgenic mice, staining of most neuronal cell 
bodies and apical dendrites of pyramidal neurons of CA1 and CA3 but not CA2 
hippocampal sector (Fig. 1D) neurons was enhanced, as also reported by Lim and 
coworkers using the T14 antibody in TauVLW mice [15]. The absence of staining in CA2 
may be due to strong transgenic position-effect variegation, since a Thy1-driven 
transgene is often stochastically and differentially expressed in subsets of neurons in 
different transgenic lines [18, 19]. 
Pyramidal neurons in sector CA1 contained the highest amounts of TauVLW limited to 
cell bodies. Granule cells of the dentate gyrus showed a lower staining with HT7 
antibody (Fig. 1D), although mossy fibers projecting to CA3 showed intense staining 
(see arrow in Fig. 1D). The level of immunostaining with HT7 antibody in CA1 is similar 
at 1.5- and 24-months old (Figs. 1D, G), but it is stronger in mossy fibers of 24-months-
old mice (see arrow in Fig. 1G). The  thionine staining revealed no differences in any 
hippocampal sector when 1.5- or 24-months-old TauVLW mice (Fig. 1E, H) were 
compared, indicating no neu- 393 
ronal loss.  
Cathepsin D analysis in hippocampus of wild type and transgenic TauVLW mice: 
Immunoblotting analysis  
Previous observations of Lim and coworkers demonstrated an increased number of 
lysosomes in neurons of TauVLW mice brains compared to wild-type animals at the 
same age [15]. To determine the possible involvement of lysosomal enzymes in the 
alterations observed in transgenic mice, we focused our study on Cathepsin D, 
evaluating its levels in the hippocampus of 1.5-, 3-, and 24-months-old TauVLW mice 
compared to wild type mice (Fig. 2A, B).  
In the hippocampus, data from western blot using R-20 antibody, which recognizes 
Cathepsin D, showed an increase of Cathepsin D levels in transgenic mice compared to 
wild type mice (Fig. 2A). This enhancement was maintained at all ages studied, as 
revealed by the statistical data analysis (∗∗∗p = 0.0001) (Fig. 2B). In wild type mice, 
Cathepsin D levels remained almost constant at 1.5- and 3-months-old, but a 
significant decrease was observed at 24-months-old (Fig. 2B).  
Together, these results showed the level of expression of CathepsinDin hippocampus 
at all ages is higher the transgenic mice than in the wild type mice, probably as a 
consequence of an increase in human mutant tau.  
Cathepsin D analysis in hippocampus of wild type and transgenic TauVLW mice: 
Immunohistochemical analysis  
To analyze the distribution and cellular localization of Cathepsin D in the hippocampus 
in wild type and transgenic mice, we performed immunohistochemistry with the same 
R-20 antibody used in the western blot analysis (Fig. 2A). Ours results indicated that 
this anti-body has a great specificity, since no immunoreactivity was detected when 
the primary antibody was omitted (data not shown). Cathepsin D immunoreactivity 
was widely distributed in neurons of the hippocampus in sagittal sections of 1.5- and 
24-months-old wild type and transgenic mice (Fig. 2C–J). Immunohistochemical 
analysis of hippocampus from TauVLW mice showed greater 
CathepsinDimmunoreactivity than did wild type mice at the ages studied (Compare 
Figs. 2C with 2D and 2E with 2F), thus confirming the results obtained in the Cathepsin 
D western blot analysis 
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(Fig. 2A). Pyramidal neurons ofCA1,CA2 (not stained with HT7), and CA3 exhibited 
intense Cathepsin D  immunostaining. At higher magnifications, semithin sections 
fromsector CA3 of the hippocampus revealed a punctuated or granular 
immunolabeling within the cytoplasm around the nucleus in most of the neurons, 
corresponding to lysosomal staining (Fig. 2G–J). Also, there was a diffuse pattern in the 
nucleus and cytoplasm in wild type and transgenic mice. At 1.5 months of age, neurons 
from CA3 of TauVLW mice presented 
 
a stronger granular staining than the wild type mice (Fig. 2G, H). Interestingly, some 
pyramidal neurons from CA3 of 24-months-old TauVLW mice showed lysosomes 
around the nucleus (Fig. 2J). 
Together these findings suggest that the distribution pattern of Cathepsin D observed 
in the hippocampus of TauVLW mice matches the regions where human mutant tau 
accumulates, probably as consequence of an increase of exogenous tau. 
Colocalization of human mutant tau with Cathepsin D in hippocampus of TauVLW mice 
In the present work, hippocampus from1.5-months old TauVLW mice showed a 
marked expression of human mutant tau, mainly in sectors CA1 and CA3. Furthermore, 
the hippocampus of 1.5-months old TauVLW mice exhibited intense Cathepsin D 
immunoreactivity (Fig. 2C–J) and increased protein levels (Fig. 2A-B). Confocal analysis 
of double  immunofluorescence staining with an antibody against Cathepsin D and the 
HT7 antibody against human tau were performed. The Cathepsin D-positive granular 
structures scattered in the soma of all neurons indicate its localization within 
lysosomes (Fig. 3, Cat D). The human mutant tau exhibited somatodendiritc 
localization (Fig. 3, HT7). In merged confocal image of a single optical section (Image 25 
of Supplementary Fig. 1), part of the human tau colocalized with Cathepsin D-positive 
vesicles in some CA1 neurons from 1.5-months-old TauVLW mice (Fig. 3, MERGE). 
Orthogonal projections of confocal merge images of Cathepsin D and TauVLW confirm 
this partial colocalization (see areas indicated by the rectangles in Fig. 3A). Double 
immunofluorescence images of each optical section could be observed in 
Supplementary Fig. 1. Similar resultswere obtainedwith CA3 neurons (data not shown). 
To investigate if this colocalization of TauVLW with Cathepsin D observed by confocal 
microscopy occurs in lysosomes, we performed subcellular fractionation and 
immunoblotting analysis in the hippocampus of 1.5-months-old TauVLW and age-
matched control mice. The purity of lysosomal fractions isolated from both groups of 
animals was confirmed by its reaction with the specific lysosomal antibodies Cathepsin 
D and LAMP2 (Fig. 3B). The lack of reaction with the specific mitochondrial (TOM 20) or 
cytoplasmatic (GADPH) antibodies confirms the purity of lysosomal fraction (Fig. 3B). 
Our results revealed that part of the TauVLW (stained with monoclonal antibody HT7; 
Fig. 3B) was in the lysosomal fraction. All these data suggest that some transgenic tau 
was already located in lysosomal compartments at early ages.  
Ultrastructural analysis of TauVLW mice  
To better define the subcellular location of human mutant tau, we performed electron 
microscopy studies in the hippocampus of TauVLW mice using the HT7 antibody.  
At light microscope resolution, no HT7 immunore-activitywas observed in semithin 
section ofCA1sector from wild type mice (Fig. 4A1), but HT7 immunostaining was very 
strong in the same neuronal populations in TauVLW mice (Fig. 4B1).  
At the ultrastructural level, several HT-7 immunopositive multivesicular bodies (MVB) 
were observed in the cytoplasm of HT7-positive CA1 hippocampal pyramidal neurons 
from 3-months-old TauVLW mice (Fig. 4B2). These immunopositive MVB showed 
vesicles homogeneously filled with immunoprecipitate as well as patches of reaction 
product over the cytoplasmic side of the MVB membrane (Fig. 4B3-5). We never found 
these immunostained MVB in wild type animals (Fig. 4A2).  
In order to confirm the presence of TauVLW in lysosomes, we performed immunogold 
electron microscopy. Fig. 5 shows a representative image of a vesicle containing 
CathepsinDpositive electron-dense material and tau immunogold particles. We did not 
find this tau immunogold staining in wild type animals (Supplementary Fig. 2).  
These electron microscope images showing the presence of both tau and Cathepsin D 
within MVB are compatible with the idea that part of human transgenic tau is localized 
in this particular lysosomal compartment, where it could be degraded.  
DISCUSSION 
Although tau plays an important role in the pathology of tauopathies, the mechanisms 
involved are not entirely understood. The use of animal models is a powerful tool to 
study some aspects of the neuropathology of these diseases. In a murine model of 
tauopathy, TauVLW mice, we previously reported that overexpression of human 
mutant tau results in hyperphosphorylation of the transgenic tau, which accumulates 
in insoluble tau polymers, accompanied increases in the number of lysosomes, which, 
moreover, display aberrant morphology [15, 20, 21]. In the present study using HT7 
antibody, we observed a somatodendritic accumulation of human mutant tau 
 
 
 in the hippocampus of TauVLW 548 mice. This increase in the cytoplasmic tau 
concentration could be related to overexpression of the transgene that saturates tau 
binding capacity in microtubules [22]. Since soluble tau has been suspected of being 
toxic for neurons [23], degradationmechanismsmight be induced in order to clear this 
toxic tau.  Tau could be degraded by the ubiquitin-proteasome system and/or the 
autophagy-lysosome pathway [5]. 
The contribution of each of these pathways to tau turnover and which forms of tau are 
degraded by each pathway is not clear and continuous being under active . It seems 
that full-length tau is cleared by the proteasome system [24, 25], because 
pharmacological inhibition of the proteasome showed accumulation of full-length tau. 
The autophagy-lysosomal pathway appears has been postulated to degrade the 
mutated and truncated forms of tau protein, some of which have pro-aggregation 
properties and may induce neurodegeneration [9]. Several evidences indicate that 
lysosomal proteases such as Cathepsins, seem to be involved in the early stages of AD 
[26]. Using bio-chemical and immunohistochemical approaches, we demonstrate an 
increase in Cathepsin D levels in the hippocampus of TauVLW mice as compared with 
wild type mice (Fig. 2). The hippocampus of TauVLW mice expresses high transgenic 
tau levels (Fig. 1) which are not degraded and then accumulate.We suggest that this 
region activates a response to tau accumulation by elevating Cathepsin D levels (Fig. 
2). Cathepsin D seems important for degrading mutant tau, as its expression was 
neuroprotective in a Drosophila tauopathy model [27].  
Our data from double immunofluorescence experiments in the hippocampus showed 
that part of HT7 immunoreactivity colocalized with some Cathepsin 
 
 
D-positive lysosomes (Fig. 3). Since in our model,  the accumulation of mutant tau does 
not increase with age, one possible interpretation is that in hippocampal neurons, 
Cathepsin D digests human mutant tau, preventing its further accumulation with age. 
This also may explain why we did not observe memory impairment in TauVLW mice at 
older ages [14]. Our results also agree with the report that tau accumulates and  forms 
insoluble aggregates when lysosomal enzymes are inhibited by chloroquine [7]. 
At the ultrastructural level, HT7 immunoreactivity was observed inside some vesicles 
within MVBs as well as in small patches over the cytoplasmic side of the membrane of 
these MVBs (Figs. 4 and 5). Since we also detected Cathepsin D immunoreactivity in 
multivesicular bodies (Supplementary Fig. 3), this particular lysosomal structure may 
be implicated in degrading human mutant tau in this murine model. Fig. 6 shows a 
model of a possible mechanism explaining howhuman mutant tau inside MVBs vesicles 
could be degraded by Cathepsin D in TauVLW mice.  
It has been recently described the presence of tau protein inMVB[28] and the 
exocytosis of thoseMVBs containing tau vesicles [29]. This mechanism could explain 
the presence of human mutant tau in brain regions that do not express the tau 
transgene in TauVLW mice [30] since MVBs have been reported to fuse  with the 
plasma membrane releasing the vesicles to the extracellular space [31]. 
In conclusion, the increased levels of Cathepsin D  observed in our murine model may 
be a compensatory response to an accumulation of human mutated tau as previously 
suggested in other studies [32, 33]. 
We now provide additional data demonstrating that some of the human mutant tau 
colocalizes with the lysosomal hydrolase Cathepsin D, suggesting that Cathepsin D 
could be partially responsible for part of tau degradation. Recently, Collin et al. [34] 
suggest that phosphorylated tau fibrils can bind to and/or get inserted into lysosomes 
and administration of tau antibody rescues the accumulation of tau pathology. 
We also show that human mutant tau accumulates within MVBs in TauVLW mice 
hippocampal neurons.  If MVBs containing human mutant tau fuse with a Cathepsin D 
lysosome, tau will be degraded. Further experiments are needed to understand how 
this human mutant tau is cleared in order to develop effective therapeutic approaches. 
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